Sichuan Kelun Pharmaceutical Co., Ltd.

Sichuan Kelun Pharmaceutical Co., Ltd. has shown strong stock performance, with notable gains over the past week and month, despite a decline in net sales and negative quarterly results. The company’s financial metrics indicate a market capitalization of CNY 36,978 million and a P/E ratio of 26.00.

Sichuan Kelun Pharmaceutical Co., Ltd. saw a significant intraday increase on March 10, 2026, contrasting with the modest gain of the China Shanghai Composite. Despite recent short-term gains, the company has struggled with declining net sales and negative quarterly results, reflecting challenges in its financial performance.

Sichuan Kelun Pharmaceutical Co., Ltd. saw a notable increase in its stock performance on March 6, 2026, reaching an intraday high. The company has outperformed the China Shanghai Composite in various timeframes, despite facing challenges such as a decline in net sales and underperformance over the past year.

Sichuan Kelun Pharmaceutical Co., Ltd. saw a notable intraday increase on March 5, 2026, despite a broader market decline. While the company has shown modest year-to-date growth, it faces challenges with slight declines over the past week and month, and significant losses over the past year and three years.